CoChat
Sign Up
Cited by 3Diabetes Management and ResearchDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Navigating Cardiovascular Risk in Type 1 Diabetes: A Comprehensive Review of Strategies for Prevention and Management

Open access
Maqusood, Shafaque, Chakole, Vivek, Dash, Sambit·2024·Cureus
DOI 10.7759/cureus.60426PMC PMC11179738
Open this paper in CoChat — free account

Abstract

Type 1 diabetes mellitus (T1DM) poses a significant cardiovascular risk, necessitating comprehensive prevention and management strategies. This review provides insights into the cardiovascular risk landscape in T1DM, emphasizing the importance of glycemic control, lipid management, blood pressure regulation, and lifestyle modifications. Pharmacological interventions, including insulin therapy and lipid-lowering medications, are discussed alongside lifestyle interventions such as diet, exercise, and smoking cessation. Early detection and management of cardiovascular complications are essential, highlighting the need for regular screening and multidisciplinary care. Patient-centered approaches, including shared decision-making and psychosocial support, are vital to effective care delivery. The review concludes with a call to action for healthcare providers and policymakers to prioritize cardiovascular risk management in T1DM. It explores future directions, including emerging therapies and technological innovations. By implementing evidence-based strategies and fostering collaboration across disciplines, we can mitigate cardiovascular risk and improve outcomes for individuals with T1DM.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7759/cureus.60426

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • By recognizing patterns, LLMs can help clinicians initiate preventive measures such as optimizing blood pressure management, prescribing statins, or recommending lifestyle changes, well before a cardiovascular event occurs.

    “By recognizing these patterns, LLMs can help clinicians initiate preventive measures, such as optimizing blood pressure management, prescribing statins, or recommending lifestyle changes, well before a cardiovascular event occurs (103).”

    From Generative artificial intelligence in predictive analysis of diabetes and its complications: a narrative review (2025) · cites this paper as [103]

    The Review (page unavailable) describes cardiovascular risk prediction in type 1 diabetes and preventive measures including blood-pressure management, statins, and lifestyle changes. It does not say that large language models recognize patterns or help clinicians initiate those measures; in this paper, “LLMs” means lipid-lowering medications. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 37

  1. [1]Type 1 diabetes - a clinical perspective Point Care Kahanovitz L Sluss PM Russell SJ 37 40 16 2017 28943810 PMC5606981
  2. [3]Exploring the complex connection between diabetes and cardiovascular disease: analyzing approaches to mitigate cardiovascular risk in patients with diabetes Cureus Jyotsna F Ahmed A Kumar K 0 15 2023 PMC10511351 37746454
  3. [4]Intensive glycemic control and cardiovascular disease: an update Nat Rev Cardiol Brown A Reynolds LR Bruemmer D 369 375 7 2010 20404853
  4. [5]Glycemic control and cardiovascular outcomes in patients with diabetes and coronary artery disease according to triglyceride-glucose index: a large-scale cohort study Cardiovasc Diabetol Lin Z He J Yuan S Song C Bian X Yang M Dou K 11 23 2024 38184572 PMC10771684
  5. [6]Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study Arch Intern Med Selvin E Coresh J Golden SH Brancati FL Folsom AR Steffes MW 1910 1916 165 2005 16157837
  6. [7]Impact of intensive glycemic treatment on diabetes complications-a systematic review Pharmaceutics Poonoosamy J Lopes P Huret P Dardari R Penfornis A Thomas C Dardari D 1791 15 2023 37513978 PMC10383300
  7. [8]Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study Diabetes Care Guy J Ogden L Wadwa RP 416 420 32 2009 19092167 PMC2646019
  8. [9]Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles Cardiovasc Diabetol Amor AJ Castelblanco E Hernández M 126 19 2020 32772924 PMC7416413
  9. [10]The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it Cardiovasc Endocrinol Metab Jenkins A Januszewski A O'Neal D 14 27 8 2019 31646294 PMC6739889
  10. [11]Treatment strategies for hypertension in patients with type 1 diabetes Expert Opin Pharmacother Katsimardou A Imprialos K Stavropoulos K Sachinidis A Doumas M Athyros VG 1241 1252 21 2020 32066278
  11. [12]Cardiovascular risk management in people with type 1 diabetes: performance using three guidelines BMJ Open Diabetes Res Care Varkevisser RD Birnie E Vollenbrock CE 10 2022 PMC9305824 35858715
  12. [13]Impact of lifestyle modifications on cardiovascular health: a narrative review Cureus Ghodeshwar GK Dube A Khobragade D 0 15 2023 PMC10460604 37641769
  13. [14]Management of diabetic hypertensives Indian J Endocrinol Metab Ganesh J Viswanathan V 0 9 15 2011 PMC3230084 22145142
  14. [16]Cardiovascular disease in type 1 diabetes Cardiovasc Endocrinol Metab Sharma H Lencioni M Narendran P 28 34 8 2019 31646295 PMC6739891
  15. [23]Physical activity and type 1 diabetes: time for a rewire? J Diabetes Sci Technol Colberg SR Laan R Dassau E Kerr D 609 618 9 2015 25568144 PMC4604550
  16. [24]Weight management in patients with type 1 diabetes and obesity Curr Diab Rep Mottalib A Kasetty M Mar JY Elseaidy T Ashrafzadeh S Hamdy O 92 17 2017 28836234 PMC5569154
  17. [25]Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms Endocr Rev Corbin KD Driscoll KA Pratley RE Smith SR Maahs DM Mayer-Davis EJ 629 663 39 2018 30060120
  18. [26]Tobacco and diabetes: clinical relevance and approach to smoking cessation in diabetic smokers Endocrinol Diabetes Nutr López Zubizarreta M Hernández Mezquita MÁ Miralles García JM Barrueco Ferrero M 221 231 64 2017 28417877
  19. [27]Impact of stopping smoking on metabolic parameters in diabetes mellitus: a scoping review World J Diabetes Walicka M Russo C Baxter M John I Caci G Polosa R 422 433 13 2022 35800409 PMC9210544
  20. [28]Exploring the smoking cessation needs of individuals with diabetes using the Information-Motivation-Behavior Skills model Tob Prev Cessat Grech J Norman IJ Sammut R 1 13 10 2024 PMC10831727 38313659
  21. [29]Type 1 diabetes and cardiovascular disease Cardiovasc Diabetol Schnell O Cappuccio F Genovese S Standl E Valensi P Ceriello A 156 12 2013 24165454 PMC3816572
  22. [30]Cardiovascular risk in type 1 diabetes mellitus Diabetes Ther Schofield J Ho J Soran H 773 789 10 2019 31004282 PMC6531592
  23. [31]Cardiovascular disease in type 1 diabetes mellitus: epidemiology and management of cardiovascular risk J Clin Med Colom C Rull A Sanchez-Quesada JL Pérez A 1798 10 2021 33924265 PMC8074744
  24. [33]Preventing cardiovascular complications in type 1 diabetes: the need for a lifetime approach Front Pediatr Chiesa ST Marcovecchio ML 696499 9 2021 34178905 PMC8219852
  25. [35]Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association Circulation de Ferranti SD de Boer IH Fonseca V 1110 1130 130 2014 25114208
  26. [39]Shared decision making in preventive health care: what it is; what it is not Can Fam Physician Grad R Légaré F Bell NR 682 684 63 2017 https://pubmed.ncbi.nlm.nih.gov/28904031/ 28904031 PMC5597010
  27. [41]Patient education and empowerment Diabetes epidemiology, genetics, pathogenesis, diagnosis, prevention, and treatment Funnell MM Anderson RM Piatt GA 485 496 Cham, Switzerland Springer International Publishing 2018 https://link.springer.com/referenceworkentry/10.1007/978-3-319-45015-5_17 · DOI
  28. [44]Diabetes mellitus and cardiovascular disease Arterioscler Thromb Vasc Biol Schmidt AM 558 568 39 2019 30786741 PMC6532416
  29. [45]Novel therapeutic agents for management of diabetes mellitus: a hope for drug designing against diabetes mellitus Life (Basel) Elkhalifa AM Nazar M Ali SI 99 14 2024 38255714 PMC10821096
  30. [46]Time trends of cardiovascular risk management in type 1 diabetes - nationwide analyses of real-life data Cardiovasc Diabetol Amadid H Clemmensen KK Vistisen D Persson F Jørgensen ME 255 21 2022 36419118 PMC9685843
  31. [47]Precision medicine in type 1 diabetes J Indian Inst Sci Michalek DA Onengut-Gumuscu S Repaske DR Rich SS 335 351 103 2023 https://link.springer.com/article/10.1007/s41745-023-00356-x#citeas 37538198 PMC10393845 · DOI
  32. [48]Precision prognostics for cardiovascular disease in type 2 diabetes: a systematic review and meta-analysis Commun Med (Lond) Ahmad A Lim LL Morieri ML 11 4 2024 38253823 PMC10803333
  33. [49]Transform diabetes care with precision medicine Health Sci Rep Kannan S Chellappan DK Kow CS 0 6 2023 PMC10616361 37915365
  34. [50]Technologies in the management of type 1 diabetes Med J Aust Snaith JR Holmes-Walker DJ 202 205 214 2021 33641181
  35. [51]Advances in technology for management of type 1 diabetes Lancet Beck RW Bergenstal RM Laffel LM Pickup JC 1265 1273 394 2019 31533908
  36. [52]Current technologies for managing type 1 diabetes mellitus and their impact on quality of life—a narrative review Life (Basel) Elian V Popovici V Ozon EA 1663 13 2023 37629520 PMC10456000
  37. [53]New and emerging technologies in type 1 diabetes Endocrinol Metab Clin North Am Sherwood JS Russell SJ Putman MS 667 678 49 2020 33153673 PMC7556222

Cited by

Sorted by citations

Authors
Maqusood, S., Chakole, V., & Dash, S.
Affiliations
Datta Meghe Institute of Higher Education and Research (IN)
Corresponding author
Maqusood, Shafaque
ORCID
Chakole, Vivek
Venue
Cureus
Publisher
Springer Science and Business Media LLC
Published
2024-05-16
Volume
16
Issue
5
Pages
e60426-e60426
ISSN
2168-8184 (ISSN-L)
DOI
10.7759/cureus.60426
PMC
PMC11179738
OpenAlex
W4396955016
Cited by
3
References
2
Citations by year
2026: 1 · 2025: 2
FWCI
0.18
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cureus (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
type 1 diabetes, cardiovascular risk, cardiovascular disease prevention, glycemic control, lipid control, blood pressure regulation, lifestyle modification, insulin therapy, lipid-lowering drugs, smoking cessation, cardiovascular screening, multidisciplinary care, shared decision-making, psychosocial support, patient-centered care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review